Using Patient Variables in CML to Guide Treatment

In the phase 1b/2 FELIX study, obecabtagene autoleucel was associated with low incidence of grade 3 or higher immune-related toxicity.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Results from a phase 1a trial showed that NX-5948 yielded an overall response rate of 77.8% in later lines of treatment for patients with WM.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Median duration on bezuclastinib was 56 weeks vs 40 weeks for placebo in non-advanced systemic mastocytosis, the phase 2 Summit trial reported.

From 2013 to 2022, the rate of important identified risks associated with ponatinib in the treatment of those with ALL or CML had decreased.